达因盖笛欣品牌怎么样 申请店铺

山东达因海洋生物制药股份有限公司成立于1994年10月，是一家高科技制药企业，注册地在山东省荣成市。公司名称原为威海达因海洋生物制药有限公司，2000年10月，因公司发展的需要，整体改制为股份公司，同时更名为山东达因海洋生物制药股份有限公司，目前公司注册资金6000万元，公司总资产达20000多万元。下设全资子公司北京达因康健医药有限责任公司。

公司主要股东为山大华特科技股份有限公司、荣成市公有资产经营有限公司和中国医学科学院医药生物技术研究所等，其中山大华特科技股份有限公司是山东大学控股的山东省高校唯一上市公司。公司的主营业务为生产销售中西药制剂及原料药、海洋生物药品，产品主要以儿童保健和治疗领域为主，产品是：伊可新（维生素AD胶囊型）、盖笛欣（复方碳酸钙泡腾颗粒剂）、伊甘欣（甘草锌颗粒剂），同时涉及内分泌、心血管、消化系统及抗感染等领域，剂型有软胶囊、硬胶囊、片剂、颗粒剂和原料药。公司管理总部设在北京，生产基地位于山东荣成，并在全国设有20多个销售分支机构。

公司现有生产基地（荣成）厂区占地面积53亩，建筑面积约2万平方米，拥有软胶囊、固体制剂等多条现代化生产线及原料药车间，所有生产线全部通过了国家GMP认证，目前年可生产软胶囊6亿粒，颗粒剂1亿袋。另外，公司已经开工建设的新厂区占地近200亩，预计2009年建成投产后将具备软胶囊12亿粒、颗粒剂10亿袋、口服液5亿支的生产能力。

公司以“使千千万万中国儿童健康强壮”为己任，致力于“成为儿童保健和治疗领域的领军企业”的宏伟战略目标，自成立以来一直以管理规范、业绩优良、成长性好在业内赢得广泛好评。1997年被山东省科委评为高新技术企业，2003年被威海市评为百佳诚信企业，2004年公司产品“伊可新”商标被评为山东省著名商标，并被评为山东省名牌产品，2008年3月“伊可新”商标又被国家工商总局评为中国“驰名保护”。公司销售收入连年增长，年平均增长率均保持在50%以上。根据国家发展和改革委员会的《中国医药统计年报》2005年公司的销售收入、利润总额进入全国化学制药工业前200强的行列。主要产品伊可新已连续九年保持同类产品市场占有率第一。

公司现有员工五百余人，是一个具有优秀的专业化素质以及强烈“责任心、进取心和事业心”和高度执行力的朝气蓬勃的团队。公司秉承“认真做事，诚信做人”的价值观，本着“勤奋、务实、高效、创新”的工作准则，努力为员工创造良好的工作氛围，搭建公司百年发展平台，保证公司稳健经营和持续发展，服务社会，贡献大众。

Shandong dyne marine biopharmaceutical Co., Ltd. was founded in October 1994. It is a high-tech pharmaceutical enterprise, registered in Rongcheng City, Shandong Province. The name of the company was originally Weihai dyne marine bio Pharmaceutical Co., Ltd. in October 2000, due to the needs of the company's development, the company was restructured as a joint-stock company as a whole, and was renamed as Shandong dyne marine bio Pharmaceutical Co., Ltd. at present, the registered capital of the company is 60 million yuan, and the total assets of the company are more than 200 million yuan. It has a wholly-owned subsidiary Beijing dyne Health Medicine Co., Ltd. The main shareholders of the company are Shanda Huate Technology Co., Ltd., Rongcheng City Public Assets Management Co., Ltd. and Institute of pharmaceutical biotechnology, Chinese Academy of Medical Sciences, etc., among which Shanda Huate Technology Co., Ltd. is the only listed company in Shandong Universities controlled by Shandong University. The main business of the company is to produce and sell Chinese and Western medicine preparations, APIs and marine biological drugs. The products are mainly in the field of children's health care and treatment. The products are: ikosin (vitamin AD capsule type), gedixin (compound calcium carbonate effervescent granules), iganxin (glycyrrhizin zinc granules). Meanwhile, they are involved in the fields of endocrine, cardiovascular, digestive system and anti infection Type A includes soft capsule, hard capsule, tablet, granule and API. The company's management headquarters is located in Beijing, the production base is located in Rongcheng, Shandong Province, and has more than 20 sales branches across the country. The company's existing production base (Rongcheng) covers an area of 53 mu, with a building area of about 20000 square meters. It has a number of modern production lines and API workshops, including soft capsules and solid preparations. All production lines have passed the national GMP certification. At present, it can produce 600 million soft capsules and 100 million bags of granules annually. In addition, the company has started the construction of a new plant area of nearly 200 mu, which is expected to have a production capacity of 1.2 billion soft capsules, 1 billion bags of granules and 500 million pieces of oral liquid when it is completed and put into operation in 2009. The company takes "making tens of millions of Chinese children healthy and strong" as its own responsibility, and is committed to the grand strategic goal of "becoming a leading enterprise in the field of children's health care and treatment". Since its establishment, it has been widely praised in the industry for its standardized management, excellent performance and good growth. In 1997, it was rated as a high-tech enterprise by Shandong Provincial Science and Technology Commission; in 2003, it was rated as one of the top 100 integrity enterprises by Weihai City; in 2004, the company's product "ikxin" trademark was rated as a famous trademark in Shandong Province, and it was rated as a famous brand product in Shandong Province; in March 2008, the "ikxin" trademark was rated as China's "well-known protection" by the State Administration of industry and commerce. The company's sales revenue has been increasing year by year, with an average annual growth rate of more than 50%. According to the annual report of China Pharmaceutical statistics issued by the national development and Reform Commission, the company's total sales revenue and profit in 2005 ranked among the top 200 in the national chemical pharmaceutical industry. The market share of its main products, icoxin, has been the first for nine consecutive years. The company has more than 500 employees. It is a vigorous team with excellent professional quality, strong sense of responsibility, enterprise and high execution. The company adheres to the value of "doing things conscientiously, being a man with integrity", and the working principle of "diligence, pragmatism, efficiency and innovation", strives to create a good working atmosphere for employees, build a century long development platform of the company, ensure the stable operation and sustainable development of the company, serve the society and contribute to the public.

本文链接： https://brand.waitui.com/f98a48d31.html